We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Any new trial would be announced by SNG first.
Given the time difference, it will be Wed am (UK) to hear any thing newsworthy.
I see Phillip Monk tweeted on 20.06.22:
Looking forward to attending the @ESWIinfluenza #ESWIsummit this week in Brussels on behalf of
@Synairgenplc
Do we know if Synairgen are sending anyone over to PMWC though probably clashes with AGM. The next 48 hours will be very interesting.
Yes, nervous times. I expect the SP to double or halve depending on if we get on a new trial or not.
Mon am was too early, make it Tue!
nessab...
We know our results were good enough to pass to P3...Furthermore,
they are looking at re-designing the trial for SNG001.... So every reason
to expect a positive report on SNG.... !!
Pressing F5 every couple of minutes, on the LSE board hoping to see an RNS..
very nervous, and where is everyone??
GLLTH,
Well Doc not long to wait....ATB!
Where's the poster with a hundred different usernames? He'll know the full facts as he's a good mate of hers won't he?!
Dare we hope she will announce P3 going ahead......!
The original date for ACTIVE-2 was by the end of June.....SO......Hopefully
it is the full results....Seems they were kept back for this presentation..
Would have thought SNG would be given the results beforehand???
RNS Wednesday morning.. ... Déjà vu anyone!!!! ???
Thanks, SYN00GOLD.
Docdaneeka- yes, likely that’s what it is. But I live in hope that it means actual, full ACTIV results for all participants :)
FNIH twitter feed
Where is the part it mentions “updating attendees on the results from the ACTIV trials”? Not doubting it says that, just sounds potentially exciting and wanted to read it myself!
If it genuinely is ALL results, including the much anticipated Synairgen P2 results, could it be more than a coincidence that our AGM is almost immediately after…?
Talk
Agent Selection and Master Protocols for Evaluation of Candidate COVID-19 Therapeutics and Lessons Learned for Future Pandemics
Working in an unprecedented timeframe, the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership rapidly designed a unique therapeutic agent intake and assessment process for multiple types of candidate treatments (preclinical and clinical antivirals, immune modulators, SARS-CoV-2 neutralizing antibodies, and organ supportive) for COVID-19, reviewing over 800 and advancing over 30 agents to trials for testing. ACTIV also developed and launched ten master protocols between April 2020 and August 2021 to allow for the coordinated and efficient evaluation of these over 30 investigational therapeutic agents. The ACTIV master protocols were designed with a portfolio approach to serve multiple patient populations with COVID-19: outpatient mild to moderately ill, inpatient moderately ill, and inpatient critically ill and designed to test the spectrum of the disease pathophysiology. Each protocol, either adaptive or pragmatic, was designed to efficiently select those treatments that provide benefit to patients while rapidly eliminating those that were either not effective or safe. For both the agent prioritization and master protocol development ACTIV has captured lessons learned that may be useful in meeting the challenges of a future pandemic.
Stacey Adam
Biography
Stacey plays a leadership role at the FNIH, helping to lead many public-private partnerships, such as Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) the PPP that evaluated hundreds of available therapeutic agents with potential application for COVID-19, prioritized them, and designed and launched multiple master protocols to test them. Stacey oversees the Cancer, Metabolic Diseases and Clinical COVID Research portfolios at the Foundation for the National Institute of Health (FNIH). Beyond ACTIV other major partnerships under her guidance include the two steering committees of the Biomarkers Consortium and their projects, Partnership for Accelerating Cancer Therapies (PACT), and the Lung Master protocol (Lung-MAP) clinical trial. Prior to FNIH, she was a Manager at Deloitte Consulting within the Federal Life Sciences and Healthcare Strategy. She received her PhD at Duke and postdoctoral training at Stanford.
Great Find SYN...... Fingers crossed!
Thanks for sharing!
GLA!
Dr Adam presents at 11.30pm UK time, hopefully RNS on Wednesday morning with A2 phase 2 results ?
FNIH’s own Stacey Adam, Associate VP of Research Partnerships, will be presenting at
@PMWCintl on 6/28. She will be sharing an overview of the ACTIV program & updating attendees on results from the ACTIV therapeutics trials.